Paragangliomas are rare, slow-growing tumors that frequently arise in the head and neck, with the carotid bodies and temporal bone of the skull base being the most common sites. These neoplasms are histologically similar to pheochromocytomas that form in the adrenal medulla and are divided into sympathetic and parasympathetic subtypes based on functionality. Skull base and head and neck region paragangliomas (SHN-PGs) are almost always derived from parasympathetic tissue and rarely secrete catecholamines. However, they can cause significant morbidity by mass effect on various cranial nerves and major blood vessels. While surgery for SHN-PG can be curative, postoperative deficits and recurrences make these lesions challenging to manage. Multiple familial syndromes predisposing individuals to development of paragangliomas have been identified, all involving mutations in the succinate dehydrogenase complex of mitochondria. Mutations in this enzyme lead to a state of “pseudohypoxia” that upregulates various angiogenic, survival, and proliferation factors. Moreover, familial paraganglioma syndromes are among the rare inherited diseases in which genomic imprinting occurs. Recent advances in gene arrays and transcriptome/exome sequencing have identified an alternate mutation in sporadic SHN-PG, which regulates proto-oncogenic pathways independent of pseudohypoxia-induced factors. Collectively these findings demonstrate that paragangliomas of the skull base and head and neck region have a distinct genetic signature from sympathetic-based paragangliomas occurring below the neck, such as pheochromocytomas. Paragangliomas serve as a unique model of primarily surgically treated neoplasms whose future will be altered by the elucidation of their genomic complexities. In this review, the authors present an analysis of the molecular genetics of SHN-PG and provide future directions in patient care and the development of novel therapies.
Please include this information when citing this paper: published online November 15, 2013; DOI: 10.3171/2013.10.JNS13659.
Albert A, , Ramirez JA, , Codere F, & Petrecca K: Sellar paraganglioma: a unique route to a rare destination case report and literature review. Clin Neurol Neurosurg 113:675–677, 2011
Arias-Stella J, & Valcarcel J: Chief cell hyperplasia in the human carotid body at high altitudes; physiologic and pathologic significance. Hum Pathol 7:361–373, 1976
Arnold A, & Papanikolaou A: Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23:4215–4224, 2005
Astrom K, , Cohen JE, , Willett-Brozick JE, , Aston CE, & Baysal BE: Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect. Hum Genet 113:228–237, 2003
Astuti D, , Latif F, , Dallol A, , Dahia PL, , Douglas F, & George E, : Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49–54, 2001
Ayala-Ramirez M, , Chougnet CN, , Habra MA, , Palmer JL, , Leboulleux S, & Cabanillas ME, : Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97:4040–4050, 2012
Badenhop RF, , Cherian S, , Lord RS, , Baysal BE, , Taschner PE, & Schofield PR: Novel mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma and sensorineural hearing loss. Genes Chromosomes Cancer 31:255–263, 2001
Bahnassy AA, , Zekri AR, , El-Houssini S, , El-Shehaby AM, , Mahmoud MR, & Abdallah S, : Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 4:22, 2004
Bakker WJ, , Weijts BG, , Westendorp B, & de Bruin A: HIF proteins connect the RB-E2F factors to angiogenesis. Transcription 4:62–66, 2013
Bayley JP, , Kunst HP, , Cascon A, , Sampietro ML, , Gaal J, & Korpershoek E, : SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol 11:366–372, 2010
Bayley JP, , van Minderhout I, , Hogendoorn PC, , Cornelisse CJ, , van der Wal A, & Prins FA, : Sdhd and SDHD/H19 knockout mice do not develop paraganglioma or pheochromocytoma. PLoS ONE 4:e7987, 2009
Baysal BE: Genomic imprinting and environment in hereditary paraganglioma. Am J Med Genet C Semin Med Genet 129C:85–90, 2004
Baysal BE, , Ferrell RE, , Willett-Brozick JE, , Lawrence EC, , Myssiorek D, & Bosch A, : Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:848–851, 2000
Baysal BE, , Willett-Brozick JE, , Lawrence EC, , Drovdlic CM, , Savul SA, & McLeod DR, : Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39:178–183, 2002
Beaulieu ME, , McDuff FO, , Frappier V, , Montagne M, , Naud JF, & Lavigne P: New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ. J Mol Recognit 25:414–426, 2012
Boedeker CC, , Erlic Z, , Richard S, , Kontny U, , Gimenez-Roqueplo AP, & Cascon A, : Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 94:1938–1944, 2009
Boedeker CC, , Neumann HP, , Maier W, , Bausch B, , Schipper J, & Ridder GJ: Malignant head and neck paragangliomas in SDHB mutation carriers. Otolaryngol Head Neck Surg 137:126–129, 2007
Brouwers FM, , Eisenhofer G, , Tao JJ, , Kant JA, , Adams KT, & Linehan WM, : High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91:4505–4509, 2006
Burnichon N, , Brière JJ, , Libé R, , Vescovo L, , Rivière J, & Tissier F, : SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19:3011–3020, 2010
Burnichon N, , Cascón A, , Schiavi F, , Morales NP, , Comino-Méndez I, & Abermil N, : MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18:2828–2837, 2012
Burnichon N, , Lepoutre-Lussey C, , Laffaire J, , Gadessaud N, , Molinié V, & Hernigou A, : A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur J Endocrinol 164:141–145, 2011
Burnichon N, , Rohmer V, , Amar L, , Herman P, , Leboulleux S, & Darrouzet V, : The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. J Clin Endocrinol Metab 94:2817–2827, 2009
Bustillo A, , Telischi F, , Weed D, , Civantos F, , Angeli S, & Serafini A, : Octreotide scintigraphy in the head and neck. Laryngoscope 114:434–440, 2004
Cascón A, , Inglada-Pérez L, , Comino-Méndez I, , de Cubas AA, , Letón R, & Mora J, : Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocr Relat Cancer 20:L1–L6, 2013
Chen J, , He L, , Dinger B, , Stensaas L, & Fidone S: Role of endothelin and endothelin A-type receptor in adaptation of the carotid body to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol 282:L1314–L1323, 2002
Chen J, , He L, , Liu X, , Dinger B, , Stensaas L, & Fidone S: Effect of the endothelin receptor antagonist bosentan on chronic hypoxia-induced morphological and physiological changes in rat carotid body. Am J Physiol Lung Cell Mol Physiol 292:L1257–L1262, 2007
Chino JP, , Sampson JH, , Tucci DL, , Brizel DM, & Kirkpatrick JP: Paraganglioma of the head and neck: long-term local control with radiotherapy. Am J Clin Oncol 32:304–307, 2009
Choudhry OJ, , Patel SK, & Liu JK, Surgery versus radiosurgery for glomus jugulare tumors. Quiñones-Hinojosa A, & Raza S: Controversies in Neuro-Oncology: Best Evidence Medicine for Brain Tumor Surgery New York, Thieme Medical, 2013. 459–469, (in press)
Comino-Méndez I, , Gracia-Aznárez FJ, , Schiavi F, , Landa I, , Leandro-García LJ, & Letón R, : Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43:663–667, 2011
de Cubas AA, , Leandro-García LJ, , Schiavi F, , Mancikova V, , Comino-Méndez I, & Inglada-Pérez L, : Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer 20:477–493, 2013
de Flines J, , Jansen J, , Elders R, , Siemers M, , Vriends A, & Hes F, : Normal life expectancy for paraganglioma patients: a 50-year-old cohort revisited. Skull Base 21:385–388, 2011
Díaz-Castro B, , Pintado CO, , García-Flores P, , López-Barneo J, & Piruat JI: Differential impairment of catecholaminergic cell maturation and survival by genetic mitochondrial complex II dysfunction. Mol Cell Biol 32:3347–3357, 2012
Dionne JM, , Wu JK, , Heran M, , Murphy JJ, , Jevon G, & White CT: Malignant hypertension, polycythemia, and paragangliomas. J Pediatr 148:540–545, 2006
Elshaikh MA, , Mahmoud-Ahmed AS, , Kinney SE, , Wood BG, , Lee JH, & Barnett GH, : Recurrent head-and-neck chemodectomas: a comparison of surgical and radiotherapeutic results. Int J Radiat Oncol Biol Phys 52:953–956, 2002
Fei P, , Wang W, , Kim SH, , Wang S, , Burns TF, & Sax JK, : Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6:597–609, 2004
Fishbein L, & Nathanson KL: Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 205:1–11, 2012
Fu M, , Wang C, , Li Z, , Sakamaki T, & Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145:5439–5447, 2004
Fujita D, , Tanabe A, , Sekijima T, , Soen H, , Narahara K, & Yamashita Y, : Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line. J Endocrinol 206:131–140, 2010
Gaal J, , Stratakis CA, , Carney JA, , Ball ER, , Korpershoek E, & Lodish MB, : SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol 24:147–151, 2011
Gottfried ON, , Liu JK, & Couldwell WT: Comparison of radiosurgery and conventional surgery for the treatment of glomus jugulare tumors. Neurosurg Focus 17:2 E4, 2004
Hahn NM, , Reckova M, , Cheng L, , Baldridge LA, , Cummings OW, & Sweeney CJ: Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 27:460–463, 2009
Hao HX, , Khalimonchuk O, , Schraders M, , Dephoure N, , Bayley JP, & Kunst H, : SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325:1139–1142, 2009
Heesterman BL, , Bayley JP, , Tops CM, , Hes FJ, , van Brussel BT, & Corssmit EP, : High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet 21:469–470, 2013
Hoegerle S, , Ghanem N, , Altehoefer C, , Schipper J, , Brink I, & Moser E, : 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30:689–694, 2003
Hsi ED, , Zukerberg LR, , Yang WI, & Arnold A: Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81:1736–1739, 1996
Hu CJ, , Wang LY, , Chodosh LA, , Keith B, & Simon MC: Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23:9361–9374, 2003
Hu YL, , DeLay M, , Jahangiri A, , Molinaro AM, , Rose SD, & Carbonell WS, : Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72:1773–1783, 2012
Ivan ME, , Sughrue ME, , Clark AJ, , Kane AJ, , Aranda D, & Barani IJ, : A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors. Clinical article. J Neurosurg 114:1299–1305, 2011
Jiang S, & Dahia PL: Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 152:2133–2140, 2011
Joshua AM, , Ezzat S, , Asa SL, , Evans A, , Broom R, & Freeman M, : Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94:5–9, 2009
Jyung RW, , LeClair EE, , Bernat RA, , Kang TS, , Ung F, & McKenna MJ, : Expression of angiogenic growth factors in paragangliomas. Laryngoscope 110:161–167, 2000
Kahn LB: Vagal body tumor (nonchromaffin paraganglioma, chemodectoma, and carotid body-like tumor) with cervical node metastasis and familial association: ultrastructural study and review. Cancer 38:2367–2377, 1976
Kantorovich V, , King KS, & Pacak K: SDH-related pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 24:415–424, 2010
Koivunen P, , Hirsilä M, , Remes AM, , Hassinen IE, , Kivirikko KI, & Myllyharju J: Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282:4524–4532, 2007
Kollert M, , Minovi AA, , Draf W, & Bockmühl U: Cervical paragangliomas-tumor control and long-term functional results after surgery. Skull Base 16:185–191, 2006
Korpershoek E, , Favier J, , Gaal J, , Burnichon N, , van Gessel B, & Oudijk L, : SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 96:E1472–E1476, 2011
Kunst HP, , Rutten MH, , de Mönnink JP, , Hoefsloot LH, , Timmers HJ, & Marres HA, : SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res 17:247–254, 2011
Künzel J, , Iro H, , Hornung J, , Koch M, , Brase C, & Klautke G, : Function-preserving therapy for jugulotympanic paragangliomas: a retrospective analysis from 2000 to 2010. Laryngoscope 122:1545–1551, 2012
Lack EE, , Perez-Atayde AR, & Young JB: Carotid body hyperplasia in cystic fibrosis and cyanotic heart disease. A combined morphometric, ultrastructural, and biochemical study. Am J Pathol 119:301–314, 1985
Langerman A, , Athavale SM, , Rangarajan SV, , Sinard RJ, & Netterville JL: Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg 138:341–345, 2012
Lapenna S, & Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547–566, 2009
Lebrin F, , Goumans MJ, , Jonker L, , Carvalho RL, , Valdimarsdottir G, & Thorikay M, : Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018–4028, 2004
Lefebvre S, , Borson-Chazot F, , Boutry-Kryza N, , Wion N, , Schillo F, & Peix JL, : Screening of mutations in genes that predispose to hereditary paragangliomas and pheochromocytomas. Horm Metab Res 44:334–338, 2012
Levy MT, , Braun JT, , Pennant M, & Thompson LD: Primary paraganglioma of the parathyroid: a case report and clinicopathologic review. Head Neck Pathol 4:37–43, 2010
Liu JK, , Christiano LD, , Gupta G, & Carmel PW: Surgical nuances for removal of retrochiasmatic craniopharyngiomas via the transbasal subfrontal translamina terminalis approach. Neurosurg Focus 28:4 E6, 2010
Liu JK, , Sameshima T, , Gottfried ON, , Couldwell WT, & Fukushima T: The combined transmastoid retro- and infralabyrinthine transjugular transcondylar transtubercular high cervical approach for resection of glomus jugulare tumors. Neurosurgery 59:1 Suppl 1 ONS115–ONS125, 2006
Martin TP, , Irving RM, & Maher ER: The genetics of paragangliomas: a review. Clin Otolaryngol 32:7–11, 2007
Maxwell PH, , Wiesener MS, , Chang GW, , Clifford SC, , Vaux EC, & Cockman ME, : The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275, 1999
Mehta V, , Fischer T, , Levi G, , Wang B, & Urken ML: Hypopharyngeal paraganglioma: case report and review of the literature. Head Neck 35:E205–E208, 2013
Mora J, , Cascón A, , Robledo M, & Catala A: Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations. Pediatr Blood Cancer 47:785–789, 2006
Netchine I, , Rossignol S, , Azzi S, , Brioude F, & Le Bouc Y: Imprinted anomalies in fetal and childhood growth disorders: the model of Russell-Silver and Beckwith-Wiedemann syndromes. Endocr Dev 23:60–70, 2012
Neumann HP, , Erlic Z, , Boedeker CC, , Rybicki LA, , Robledo M, & Hermsen M, : Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res 69:3650–3656, 2009
Neumann HP, , Pawlu C, , Peczkowska M, , Bausch B, , McWhinney SR, & Muresan M, : Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292:943–951, 2004
Neumann HP, , Sullivan M, , Winter A, , Malinoc A, , Hoffmann MM, & Boedeker CC, : Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab 96:E1279–E1282, 2011
Offergeld C, , Brase C, , Yaremchuk S, , Mader I, , Rischke HC, & Gläsker S, : Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo) 67:Suppl 1 19–28, 2012
Papaspyrou K, , Mann WJ, & Amedee RG: Management of head and neck paragangliomas: review of 120 patients. Head Neck 31:381–387, 2009
Papaspyrou K, , Welkoborsky HJ, , Gouveris H, & Mann WJ: Malignant and benign sinonasal paragangliomas. Laryngoscope 123:1830–1836, 2013
Peczkowska M, , Cascon A, , Prejbisz A, , Kubaszek A, , Cwikła BJ, & Furmanek M, : Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 4:111–115, 2008
Pham TH, , Moir C, , Thompson GB, , Zarroug AE, , Hamner CE, & Farley D, : Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 118:1109–1117, 2006
Pollard PJ, , El-Bahrawy M, , Poulsom R, , Elia G, , Killick P, & Kelly G, : Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91:4593–4598, 2006
Qin Y, , Yao L, , King EE, , Buddavarapu K, , Lenci RE, & Chocron ES, : Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 42:229–233, 2010
Rabinovitz S, , Kaufman Y, , Ludwig G, , Razin A, & Shemer R: Mechanisms of activation of the paternally expressed genes by the Prader-Willi imprinting center in the Prader-Willi/Angelman syndromes domains. Proc Natl Acad Sci U S A 109:7403–7408, 2012
Reik W, , Dean W, & Walter J: Epigenetic reprogramming in mammalian development. Science 293:1089–1093, 2001
Ricketts C, , Woodward ER, , Killick P, , Morris MR, , Astuti D, & Latif F, : Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100:1260–1262, 2008
Salame K, , Ouaknine GE, , Yossipov J, & Rochkind S: Paraganglioma of the pituitary fossa: diagnosis and management. J Neurooncol 54:49–52, 2001
Sánchez-Elsner T, , Botella LM, , Velasco B, , Langa C, & Bernabéu C: Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277:43799–43808, 2002
Schiavi F, , Boedeker CC, , Bausch B, , Peçzkowska M, , Gomez CF, & Strassburg T, : Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294:2057–2063, 2005
Selak MA, , Armour SM, , MacKenzie ED, , Boulahbel H, , Watson DG, & Mansfield KD, : Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85, 2005
Span PN, , Rao JU, , Oude Ophuis SB, , Lenders JW, , Sweep FC, & Wesseling P, : Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma. Endocr Relat Cancer 18:323–331, 2011
Srirangalingam U, , Walker L, , Khoo B, , MacDonald F, , Gardner D, & Wilkin TJ, : Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B (SDH-B) gene mutation carriers. Clin Endocrinol (Oxf) 69:587–596, 2008
Suárez C, , Rodrigo JP, , Mendenhall WM, , Hamoir M, , Silver CE, & Grégoire V, : Carotid body paragangliomas: a systematic study on management with surgery and radiotherapy. Eur Arch Otorhinolaryngol [epub ahead of print] 2013
van der Mey AG, , Maaswinkel-Mooy PD, , Cornelisse CJ, , Schmidt PH, & van de Kamp JJ: Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 2:1291–1294, 1989
van Hulsteijn LT, , Corssmit EP, , Coremans IE, , Smit JW, , Jansen JC, & Dekkers OM: Regression and local control rates after radiotherapy for jugulotympanic paragangliomas: systematic review and meta-analysis. Radiother Oncol 106:161–168, 2013
Wang X, , Ma S, & Qi G: Effect of hypoxia-inducible factor 1-alpha on hypoxia/reoxygenation-induced apoptosis in primary neonatal rat cardiomyocytes. Biochem Biophys Res Commun 417:1227–1234, 2012
Wasserman PG, & Savargaonkar P: Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngol Clin North Am 34:845–862, v–vi, 2001
Weir EK, , López-Barneo J, , Buckler KJ, & Archer SL: Acute oxygen-sensing mechanisms. N Engl J Med 353:2042–2055, 2005
White JB, , Link MJ, & Cloft HJ: Endovascular embolization of paragangliomas: a safe adjuvant to treatment. J Vasc Interv Neurol 1:37–41, 2008
Wick MR: Neuroendocrine neoplasia. Current concepts. Am J Clin Pathol 113:331–335, 2000
Zheng X, , Wei S, , Yu Y, , Xia T, , Zhao J, & Gao S, : Genetic and clinical characteristics of head and neck paragangliomas in a Chinese population. Laryngoscope 122:1761–1766, 2012
Zhuang Z, , Yang C, , Lorenzo F, , Merino M, , Fojo T, & Kebebew E, : Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med 367:922–930, 2012